These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 2951221)

  • 1. Comparison of glycaemic control in diabetic patients treated with morning or evening human ultratard insulin.
    Edsberg B; Dejgaard A; Kühl C
    Diabet Med; 1987; 4(1):53-5. PubMed ID: 2951221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of early-morning hyperglycemia in IDDM patients with long-acting zinc insulin.
    Parillo M; Mura A; Iovine C; Rivellese AA; Lavicoli M; Riccardi G
    Diabetes Care; 1992 Feb; 15(2):173-7. PubMed ID: 1547673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue.
    Jørgensen S; Vaag A; Langkjaer L; Hougaard P; Markussen J
    BMJ; 1989 Aug; 299(6696):415-9. PubMed ID: 2506998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in morning hyperglycaemia with basal human ultratard and prandial human actrapid insulin--a comparison of multiple injection regimens.
    Davies RR; McEwen J; Moreland TA; Durnin C; Newton RW
    Diabet Med; 1988 Oct; 5(7):671-5. PubMed ID: 2975553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Miscibility of semisynthetic human ultralente insulin with short-acting insulin in insulin-dependent diabetic patients.
    Lunetta M; di Mauro M; Crimi S; Sudano L; Mughini L
    Acta Diabetol Lat; 1988; 25(3):263-9. PubMed ID: 3071068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Action profile of human ultralente insulin compared with human NPH-insulin].
    Starke AA; Heinemann L; Hohmann A; Berger M
    Dtsch Med Wochenschr; 1989 Apr; 114(16):618-22. PubMed ID: 2651061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ultratard HM, a new human insulin. Advantages as compared to current preparations?].
    Saner B; Fankhauser S
    Schweiz Med Wochenschr; 1986 Jan; 116(4):116-9. PubMed ID: 3513303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Monotard and Ultratard insulin at bedtime in a model of optimized insulin therapy in Italy.
    Martina V; Tagliabue M; Maccario M; D'Antona G; Camanni F
    Diabete Metab; 1989; 15(6):372-4. PubMed ID: 2697606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of human ultralente is limited by great intraindividual variability in overnight plasma insulin profiles.
    Lindström T; Olsson PO; Arnqvist HJ
    Scand J Clin Lab Invest; 2000 Aug; 60(5):341-7. PubMed ID: 11003253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 'dawn phenomenon' in adolescents with insulin dependent diabetes mellitus: possible contribution of insulin-like growth factor binding protein-1.
    Cotterill AM; Daly F; Holly JM; Hughes SC; Camacho-Hübner C; Abdulla AF; Gale EA; Savage MO
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):567-74. PubMed ID: 8548941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of morning and bed-time ultralente administration when using multiple injections in adolescence.
    Smith CP; Dunger DB; Mitten S; Hewitt J; Spowart K; Grant DB; Savage MO
    Diabet Med; 1988; 5(4):352-5. PubMed ID: 2968885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mixtures of human intermediate and human regular insulin in type 1 diabetic patients. Evaluation of free insulin levels and insulin action on glucose metabolism after combined and separate subcutaneous administration.
    Klauser R; Schernthaner G; Prager R
    Diabetes Res Clin Pract; 1988 Sep; 5(3):185-90. PubMed ID: 3065016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of mixing human soluble and human crystalline zinc-suspension insulin: plasma insulin and blood glucose profiles after subcutaneous injection.
    Francis AJ; Hanning I; Alberti KG
    Diabet Med; 1985 May; 2(3):177-80. PubMed ID: 2952414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes.
    Porcellati F; Lucidi P; Cioli P; Candeloro P; Marinelli Andreoli A; Marzotti S; Ambrogi M; Bolli GB; Fanelli CG
    Diabetes Care; 2015 Mar; 38(3):503-12. PubMed ID: 25524950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of short-term basal insulin supplementation with human ultralente insulin on diurnal glycemic control in NIDDM patients.
    Iwamoto Y; Matsuda A; Sakamoto Y; Kuzuya T
    Diabetes Res Clin Pract; 1987; 3(6):337-41. PubMed ID: 3311680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of site and timing of the morning insulin injection in type 1 diabetes.
    Witt MF; White NH; Santiago JV
    J Pediatr; 1983 Oct; 103(4):528-33. PubMed ID: 6352884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents.
    Del Prato S; Vigili de Kreutzenberg S; Riccio A; Maifreni L; Duner E; Lisato G; Iavicoli M; Tiengo A
    Diabetologia; 1990 Nov; 33(11):688-95. PubMed ID: 2127573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.